Aaron S Kesselheim1,2, Joshua J Gagne3,4, Jessica M Franklin3,4, Wesley Eddings3,4, Lisa A Fulchino3,4, Jerry Avorn3,4, Eric G Campbell5,4. 1. Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, 1620 Tremont Street Suite 3030, Boston, MA, USA. akesselheim@partners.org. 2. Harvard Medical School, Boston, MA, USA. akesselheim@partners.org. 3. Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, 1620 Tremont Street Suite 3030, Boston, MA, USA. 4. Harvard Medical School, Boston, MA, USA. 5. Mongan Institute for Health Policy, Massachusetts General Hospital, Boston, MA, USA.
Abstract
BACKGROUND: Over 84 % of all prescriptions in the US are filled as generic drugs, though in prior surveys, patients reported concerns about their quality. OBJECTIVE: We aimed to survey patients' perceptions and use of generic drugs. DESIGN: Our survey (administered August 2014) assessed patients' skepticism about generic drug safety and effectiveness and how often they requested brand-name drugs. Chi-square tests and two-sample t-tests assessed associations between patient demographics and the outcomes. PARTICIPANTS: Our sample frame was the CVS Advisor Panel, a national database of 124,621 CVS customers. We randomly selected 1450 patients with self-reported chronic conditions who filled at least one prescription in the prior 3 months. MAIN MEASURES: We assessed how often patients reported asking their physicians to prescribe a brand-name over a generic drug in the last year, and "generic skepticism," defined as not believing generic drugs were as safe, effective, had the same side effects, and contained the same active ingredients as brand-name drugs. KEY RESULTS: Of the 1,442 patients with valid addresses, 933 responded (65 % response rate) and 753 took the full survey. A vast majority (83 %) agreed that physicians should prescribe generic drugs when available, and 54 % said they had not asked their physicians to prescribe a brand-name drug over a generic in the past year. Most respondents considered generic drugs to be as effective (87 %) and safe (88 %) as their brand-name counterparts, and to have the same side effects (80 %) and active ingredients (84 %). Non-Caucasians were more likely than Caucasians to request a brand-name drug over a generic (56 % vs. 43 %, p < 0.01), and were also more skeptical of generic drugs' clinical equivalence (43 % vs. 29 %, p < 0.01). CONCLUSIONS: We found a substantial shift towards more patients having positive views of generic drugs, but lingering negative perceptions will have to be overcome to ensure continued cost-savings and improved patient outcomes from generic drugs.
BACKGROUND: Over 84 % of all prescriptions in the US are filled as generic drugs, though in prior surveys, patients reported concerns about their quality. OBJECTIVE: We aimed to survey patients' perceptions and use of generic drugs. DESIGN: Our survey (administered August 2014) assessed patients' skepticism about generic drug safety and effectiveness and how often they requested brand-name drugs. Chi-square tests and two-sample t-tests assessed associations between patient demographics and the outcomes. PARTICIPANTS: Our sample frame was the CVS Advisor Panel, a national database of 124,621 CVS customers. We randomly selected 1450 patients with self-reported chronic conditions who filled at least one prescription in the prior 3 months. MAIN MEASURES: We assessed how often patients reported asking their physicians to prescribe a brand-name over a generic drug in the last year, and "generic skepticism," defined as not believing generic drugs were as safe, effective, had the same side effects, and contained the same active ingredients as brand-name drugs. KEY RESULTS: Of the 1,442 patients with valid addresses, 933 responded (65 % response rate) and 753 took the full survey. A vast majority (83 %) agreed that physicians should prescribe generic drugs when available, and 54 % said they had not asked their physicians to prescribe a brand-name drug over a generic in the past year. Most respondents considered generic drugs to be as effective (87 %) and safe (88 %) as their brand-name counterparts, and to have the same side effects (80 %) and active ingredients (84 %). Non-Caucasians were more likely than Caucasians to request a brand-name drug over a generic (56 % vs. 43 %, p < 0.01), and were also more skeptical of generic drugs' clinical equivalence (43 % vs. 29 %, p < 0.01). CONCLUSIONS: We found a substantial shift towards more patients having positive views of generic drugs, but lingering negative perceptions will have to be overcome to ensure continued cost-savings and improved patient outcomes from generic drugs.
Authors: L Ebony Boulware; Lisa A Cooper; Lloyd E Ratner; Thomas A LaVeist; Neil R Powe Journal: Public Health Rep Date: 2003 Jul-Aug Impact factor: 2.792
Authors: Li-Ling Huang; James F Thrasher; Erika Nayeli Abad; K Michael Cummings; Maansi Bansal-Travers; Abraham Brown; Gera E Nagelhout Journal: Health Educ Behav Date: 2015-01-14
Authors: Francesco Dentali; Marco P Donadini; Nathan Clark; Mark A Crowther; David Garcia; Elaine Hylek; Dan M Witt; Walter Ageno Journal: Pharmacotherapy Date: 2011-04 Impact factor: 4.705
Authors: William H Shrank; Joshua N Liberman; Michael A Fischer; Jerry Avorn; Elaine Kilabuk; Andrew Chang; Aaron S Kesselheim; Troyen A Brennan; Niteesh K Choudhry Journal: Am J Med Date: 2011-04 Impact factor: 4.965
Authors: William H Shrank; Emily R Cox; Michael A Fischer; Jyotsna Mehta; Niteesh K Choudhry Journal: Health Aff (Millwood) Date: 2009 Mar-Apr Impact factor: 6.301
Authors: Joshua J Gagne; Niteesh K Choudhry; Aaron S Kesselheim; Jennifer M Polinski; David Hutchins; Olga S Matlin; Troyen A Brennan; Jerry Avorn; William H Shrank Journal: Ann Intern Med Date: 2014-09-16 Impact factor: 25.391
Authors: Richard A Hansen; Jingjing Qian; Richard Berg; James Linneman; Enrique Seoane-Vazquez; Sarah K Dutcher; Saeid Raofi; C David Page; Peggy Peissig Journal: Pharmacotherapy Date: 2017-03-20 Impact factor: 4.705
Authors: Jennifer N Howard; Ilene Harris; Gavriella Frank; Zippora Kiptanui; Jingjing Qian; Richard Hansen Journal: Res Social Adm Pharm Date: 2017-08-04
Authors: Ameet Sarpatwari; Joshua J Gagne; Zhigang Lu; Eric G Campbell; Wendy J Carman; Cheryl L Enger; Sarah K Dutcher; Wenlei Jiang; Aaron S Kesselheim Journal: J Gen Intern Med Date: 2019-01-10 Impact factor: 5.128
Authors: Y Alatawi; Md M Rahman; N Cheng; J Qian; P L Peissig; R L Berg; C D Page; R A Hansen Journal: J Clin Pharm Ther Date: 2017-11-01 Impact factor: 2.512
Authors: Md Motiur Rahman; Yasser Alatawi; Ning Cheng; Jingjing Qian; Peggy L Peissig; Richard L Berg; David C Page; Richard A Hansen Journal: Clin Drug Investig Date: 2017-12 Impact factor: 2.859
Authors: Tianna Zhou; Patrick Liu; Sanket S Dhruva; Nilay D Shah; Reshma Ramachandran; Karina M Berg; Joseph S Ross Journal: JAMA Intern Med Date: 2022-02-01 Impact factor: 44.409
Authors: Bridget J Kelly; Douglas J Rupert; Kathryn J Aikin; Helen W Sullivan; Mihaela Johnson; Carla M Bann; Nicole Mack; Brian G Southwell; Sue West; Sarah Parvanta; Alexander Rabre; Susana Peinado Journal: Res Social Adm Pharm Date: 2020-08-06